Yuichiro Sugawara

Yuichiro Sugawara

Speaker
CEO, AMS Planning, Inc.

AMS is a nuclear medicine start-up executing new business and economic growth opportunities in Japan and the Asian region based on next-generation targeted radiopharmaceuticals. We are in-process of bringing a new prostate cancer diagnostic capability to the Japanese market in addition to working on the treatment side. There are two market trends driving AMS’ strategic growth plan: (1) the March 2011 Nuclear Power Station Accident in Japan, and (2) the Japanese phase-out of Russian radioisotope imports starting in 2022. Since February 2020, utilizing approximately $1.5M in funding, AMS has built a talented team of medical, technical and business experts to progress pre-clinical R&D in preparation for Phase 1 clinical trial of 68Ga PSMA-11 PET in Recurrent Prostate Cancer scheduled in 1Q 2023. AMS seeks to raise $10M for Phase 2 and will execute bridging studies in the United States to omit Phase 3 clinical trial, reducing PMDA approval timelines and accelerating our time to market. In addition, AMS is partnering with several well-known Japanese medical institutes to develop actinium225 (Ac225) bearing cancer treatment drugs based upon a proprietary research and development plan. AMS also seeks to raise $10M to expand our business to secure long-term, stable supplies of vital medical isotopes, including Ac225 from the U.S., and seed funds for developing new treatments with Japanese research institutions and hospitals.
Connect
UPCOMING SESSIONS BY THIS SPEAKER
Connect
PAST EVENTS
Learn
Articles